Frazier Healthcare Partners
Seattle, Washington, United StatesFounded 1991
Frazier Healthcare Partners is a healthcare-focused private equity and venture capital firm founded in 1991 and headquartered in Seattle, Washington. The firm specializes in growth buyout and venture investments exclusively in the healthcare sector, including healthcare services, life sciences, pharmaceuticals, and medical products.
35% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $78.9M (across 90 rounds with reported amounts).
Portfolio
74
Fund Size
$2.3B
Top Stage
Series A
Last 12 Mo
5
Team
NN
Nader Naini
Managing Partner
NE
Nathan Every, MD
General Partner
BH
Ben Hansen
CoE - Partner, Finance & Operations
BA
Brad Alexander
CoE - Partner, Finance & Operations
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
101 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 RQ Bio | Series A | $115M | Jun 2026 |
| VVima | Series A | $100M | Mar 2026 |
| RRq Biotechnology Ltd | Series A | $115M | Jan 2026 |
 Iolyx Therapeutics | Series B | $15M | Dec 2025 |
| BBraveheart Bio | Series A | $185M | Nov 2025 |
 Callio Therapeutics | Series A | $187M | Mar 2025 |
 Alesta Therapeutics | Series A | — | Jan 2025 |
| SStar Tx | Series D | $125M | Jan 2025 |
| HHillstar | Series A | $67M | Jan 2025 |
 Alentis Therapeutics | Series D | $181.4M | Nov 2024 |
 Halda | Series B | $126M | Aug 2024 |
 Sudo Biosciences | Series B | $147M | Jan 2024 |
| SStar Tx | Series C | — | Jan 2023 |
| AAlpha-9 Theranostics | Series B | $75M | Dec 2022 |
| MMbx Biosciences Inc | Series B | $115M | Nov 2022 |
| SSanreno Therapeutics | Unknown | $40M | Nov 2021 |
 HilleVax | Unknown | $135M | Sep 2021 |
| HHillevax, Inc. | Unknown | $135M | Sep 2021 |
 Sonoma Biotherapeutics | Series B | $265M | Aug 2021 |
 Hummingbird Bioscience | Series C | $125M | May 2021 |
 Amunix | Series B | $117M | Mar 2021 |
| AAmunix Pharmaceuticals | Series B | $117M | Mar 2021 |
 Seraxis | Series C | $40M | Feb 2021 |
| AAmunix Pharmaceuticals | Series B | $117M | Jan 2021 |
 Scorpion Therapeutics | Series A | $102M | Jan 2021 |
Page 1 of 5
Top Co-Investors
Frazier Life Sciences23 shared
OrbiMed15 shared
Longitude Capital13 shared
Omega Funds13 shared
RA Capital Management11 shared
Pivotal Life Sciences8 shared
Novo Capital8 shared
Canaan Partners8 shared
Domain Associates8 shared
Vivo Capital7 shared
Novo Holdings A/S7 shared
Amgen Ventures7 shared
Samsara BioCapital6 shared
Osage University Partners6 shared
New Leaf Venture Partners6 shared
Venrock6 shared
Polaris Partners6 shared
Bain Capital Life Sciences6 shared
Atlas Venture6 shared
Last updated: 7 September 2026